Structure of Teniposide
CAS No.: 29767-20-2
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Teniposide, a derivative of podophyllotoxin, can interact with DNA topoisomerase II and is used in cancer medicine.
Synonyms: VM26; NSC 122819; HSDB 6546
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
| CAS No. : | 29767-20-2 |
| Formula : | C32H32O13S |
| M.W : | 656.65 |
| SMILES Code : | O=C1OC[C@]2([H])[C@H](O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO4)O3)O[C@@H]4C5=CC=CS5)O)O)C6=C(C=C7OCOC7=C6)[C@@H](C8=CC(OC)=C(O)C(OC)=C8)[C@]21[H] |
| Synonyms : |
VM26; NSC 122819; HSDB 6546
|
| MDL No. : | MFCD00866516 |
| InChI Key : | NRUKOCRGYNPUPR-QBPJDGROSA-N |
| Pubchem ID : | 452548 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302-H351-H361 |
| Precautionary Statements: | P280-P305+P351+P338 |
| Target |
|
In Vitro:
|
Cell Line
|
Concentration | Treated Time | Description | References |
| MDA-MB-231 | 500 nM | 24 hours | To assess the effect of Teniposide on cell viability, results showed minimal impact on cell viability at low concentrations. | Cell Death Dis. 2024 May 8;15(5):322. |
| Glioblastoma stem-like cells (GSCs) | 0.5 µM | 24 hours | To evaluate the cytotoxic effect of Teniposide on GSCs under normoxic and hypoxic conditions. Results showed that Teniposide decreased GSC viability under normoxia but no changes were observed under hypoxia, indicating hypoxia enhances chemoresistance of GSCs to Teniposide. | Int J Mol Sci. 2022 Aug 12;23(16):9022. |
| MDA-MB-231-1833 | 500 nM | 5 days | To evaluate the effect of Teniposide on 3D growth morphology, results showed Teniposide significantly reduced invasive growth morphology. | Cell Death Dis. 2024 May 8;15(5):322. |
In Vivo:
|
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
| BALB/c mice | CT26 tumor model | Intraperitoneal injection | 10 mg/kg | Once on day 6 and once on day 7 | To evaluate the inhibitory effect of Teniposide on tumor growth and its impact on immune cell infiltration in the tumor microenvironment. Results showed that Teniposide significantly inhibited tumor growth and increased the number and activity of tumor-infiltrating CD8+ T cells. | J Clin Invest. 2019 Aug 13;129(11):4850-4862 |
| C57BL/6J mice | Hepa1-6 liver orthotopic tumor model | Intraperitoneal injection | 10 mg/kg | Twice, interval not specified | Evaluate the effect of HBO combined with teniposide treatment on the efficacy of PD-1 antibody. Results showed that HBO significantly enhanced teniposide-induced cGAS-STING-dependent tumor type I interferon and NF-κB signaling, both of which contributed to the activation of dendritic cells and subsequent cytotoxic T cells. | J Immunother Cancer. 2022 Aug;10(8):e004006 |
| Nude mice | Breast cancer lung metastasis model | Tail vein injection | 500 nM | Single injection, observed for 21 days | To assess the effect of Teniposide on breast cancer lung metastasis, results showed Teniposide significantly reduced the formation of lung metastatic colonies. | Cell Death Dis. 2024 May 8;15(5):322. |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT00198991 | Adult Acute Lymphocytic Leukem... More >>ia Less << | Phase 4 | Unknown | - | Germany ... More >> University of Frankfurt, Medical Dept. II Recruiting Frankfurt, Germany, 60590 Contact: Dieter Hoelzer, MD,PhD ++49(0)69 6301 5194 hoelzer@em.uni-frankfurt.de Contact: Nicola Goekbuget, MD ++49(0)69 6301 6365 goekbuget@em.uni-frankfurt.de Principal Investigator: Dieter Hoelzer, MD,PhD Sub-Investigator: Nicola Goekbuget, MD Less << |
| NCT02086942 | Multiple Myeloma | Phase 2 | Recruiting | August 2017 | China, Jiangsu ... More >> Jinling Hospital Recruiting Nanjing, Jiangsu, China, 210002 Contact: zhai yo ping, doctor 13951947646 ypzhai@medmail.com.cn Less << |
| NCT00199004 | Adult Acute Lymphocytic Leukem... More >>ia Less << | Phase 4 | Completed | - | Germany ... More >> University Hospital of Frankfurt, Medical Dept. II Frankfurt, Germany, 60590 Less << |
| NCT00199056 | Adult Acute Lymphocytic Leukem... More >>ia Less << | Phase 4 | Completed | - | Germany ... More >> University Hospital, Medical Dept. II Frankfurt, Germany, 60590 Less << |
| NCT00199095 | Adult Acute Lymphocytic Leukem... More >>ia Less << | Phase 4 | Completed | - | Germany ... More >> University Hospital, Medical Dept. II Frankfurt, Germany, 60590 Less << |
| NCT00002531 | Leukemia | Phase 2 | Unknown | - | Germany ... More >> Klinikum der J.W. Goethe Universitaet Frankfurt, Germany, D-60590 Less << |
| NCT02645864 | Esophageal Squamous Cell Carci... More >>noma Less << | Phase 1 | Recruiting | December 2017 | China, Beijing ... More >> Peking University Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Xiaodong Zhang 86-10-88196961 zxd0829@hotmail.com Principal Investigator: Xiaodong Zhang Less << |
| NCT00187083 | Acute Lymphoblastic Leukemia | Phase 3 | Completed | - | United States, Tennessee ... More >> St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 Less << |
| NCT00343369 | Leukemia | Not Applicable | Unknown | - | Germany ... More >> Evangelisches Krankenhauus Bielfeld Recruiting Biefeld, Germany, 33617 Contact: N. Jorch, MD 49-52-177-278-050 Klinikum Bremen-Mitte Recruiting Bremen, Germany, D-28205 Contact: Arnulf Pekrun, MD, PhD 49-421-497-3656 arnulf.pekrun@klinikum-bremen-mitte.de Universitaetsklinikum Duesseldorf Recruiting Duesseldorf, Germany, D-40225 Contact: Contact Person 49-211-311-7990 Universitats - Kinderklinik Recruiting Greiswald, Germany, 17487 Contact: James F. Beck, MD 49-383-486-6325 beck@uni-greifswald.de University Medical Center Hamburg - Eppendorf Recruiting Hamburg, Germany, D-20246 Contact: Gritta Janka-Schaub 49-404-2803-2580 Kreskrankenhaus Kinderabteilung Recruiting Heide, Germany, 25746 Contact: Streitberger 49-481-785-911 Clinic for Bone Marrow Transplantation and Hematology and Oncology Recruiting Idar-Oberstein, Germany, D-55743 Contact: Wenzel Nuernberger, MD, PhD 49-6781-66-1582 wnuernberger@bmt-center-io.com Klinikum Krefeld GmbH Recruiting Krefeld, Germany, D-47805 Contact: P. Thomas 49-2151-322-375 Universitaets - Kinderklinik Recruiting Leipzig, Germany, D-04317 Contact: Dieter Koerholz, MD 49-341-9726-246 koerd@medizin.uni-leipzig.de Johannes Gutenberg University Recruiting Mainz, Germany, D-55101 Contact: P. Gutjahr, MD 49-6131-17-2112 Krankenhaus Neuwerk Klinik fuer Kinder und Jugendmedizin Recruiting Moenchengladbach, Germany, D-41066 Contact: Wolfgang Mueller, MD 49-2161-668-2481 Dr. von Haunersches Kinderspital der Universitaet Muenchen Recruiting Munich, Germany, D-80337 Contact: Arndt Borkhardt 49-89-5160-4498 Staedtisches Krankenhaus Muenchen - Harlaching Recruiting Munich, Germany, D-81545 Contact: Papucek 49-89-6210-2710 Klinik St. Hedwig-Kinderklinik Recruiting Regensburg, Germany, 93049 Contact: Ove Peters 49-941-369-5404 Dr. Horst-Schmidt-Kliniken Recruiting Wiesbaden, Germany, D-65199 Contact: Gerhard Beron, MD 49-611-43-2564 Helios Kliniken Wuppertal University Hospital Recruiting Wuppertal, Germany, D-42283 Contact: B. Dohrn, MD 49-202-896-3823 bdohrn@wuppertal.helios-klinikum.de Less << |
| NCT00199069 | Adult Acute Lymphocytic Leukem... More >>ia Less << | Phase 4 | Completed | - | Germany ... More >> University Hospital, Medical Dept. II Frankfurt, Germany Less << |
| NCT02788201 | Urothelial Carcinoma ... More >> Bladder Cancer Urinary Bladder Neoplasms Less << | Phase 2 | Recruiting | July 1, 2020 | United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 Less << |
| NCT01290120 | Burkitt Lymphoma ... More >> B-ALL Less << | Phase 2 | Completed | - | Italy ... More >> Divisione di Ematologia e TMO, Ospedale San Maurizio Bolzano, (bz), Italy Ematologia e centro TMO - Ospedale Armando Businco Cagliari, (ca), Italy S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle Cuneo, (cn), Italy Onco-Ematologia - Ospedale Civile Noale, (ve), Italy Dipartimento di Ematologia e Medicina Trasfusionale - Azienda Osp. Nazionale Santi Antonio e Biagio e Cesare Arrigo Alessandria, AL, Italy USC Ematologia Ospedali Riuniti di Bergamo Bergamo, BG, Italy Divisione Ematologia Spedali Civili Brescia, BS, Italy, 25123 Ematologia - AOU Careggi Firenze, FI, Italy Ematologia e TMO - Ospedale San Raffaele Milano, MI, Italy Ematologia - TMO - Ospedale San Gerardo Monza, MI, Italy Ematologia Ospedale San Bortolo Vicenza, VI, Italy, 36100 USC Ematologia Ospedali Riuniti di Bergamo Bergamo, Italy, 24128 Less << |
| NCT02290132 | - | Unknown | July 2017 | China, Shanghai ... More >> Shanghai First People's HOSPITAL Recruiting Shanghai, Shanghai, China, 200127 Contact: YANG JUN, master 13564880726 yangjuan74@hotmail.com Contact: wang chun, doctor 13386259777 wangchun2@medmail.com.cn Less << | |
| NCT00004231 | Lymphoma | Phase 2 | Completed | - | United States, Illinois ... More >> Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago, Illinois, United States, 60611 Less << |
| NCT01430013 | T Cell Lymphoma | Phase 2 | Unknown | December 2015 | China, Tianjin ... More >> Tianjin Medical University Cancer Institute and Hospital Tianjin, Tianjin, China, 300060 Less << |
| NCT00853008 | Acute Lymphoblastic Leukemia | Phase 4 | Active, not recruiting | January 2019 | Spain ... More >> Hospital General Alicante, Spain Hospital Germans Trias i Pujol Badalona, Spain Clínica Teknon Barcelona, Spain Hospital Clínic i Provincial Barcelona, Spain Hospital de Sant Pau Barcelona, Spain Hospital Duran y Reynals Barcelona, Spain Hospital Vall d'Hebrón Barcelona, Spain Hospital General Castellón, Spain Hospital San Pedro de Alcántara Cáceres, Spain Hospital Puerta del Mar Cádiz, Spain Hospital Josep Trueta Girona, Spain Hospital Universitario Guadalajara, Spain Hospital Juan Canalejo La Coruña, Spain Hospital Xeral Lugo, Spain Hospital 12 de Octubre Madrid, Spain Hospital Clínico Universitario Madrid, Spain Hospital de Fuenlabrada Madrid, Spain Hospital Ramón y Cajal Madrid, Spain Hospital Morales Messeguer Murcia, Spain Hospital Carlos Haya Málaga, Spain Hospital Virgen de la Victoria Málaga, Spain Hospital Central de Asturias Oviedo, Spain Hospital Son Llàtzer Palma de Mallorca, Spain Clínica Universitaria de Navarra Pamplona, Spain Hospital Parc Taulí Sabadell, Spain Hospital Clínico Universitario Salamanca, Spain Hospital Marqués de Valdecilla Santander, Spain Hospital Xeral Santiago, Spain Hospital Virgen del Rocio Sevilla, Spain Hospital Joan XXIII Tarragona, Spain Hospital Mútua de Terrassa Terrassa, Spain Hospital Clínico Universitario Valencia, Spain Hospital Dr Pesset Valencia, Spain Hospital General Valencia, Spain Hospital La Fe Valencia, Spain Hospital Clínico Valladolid, Spain Hospital Virgen de la Concha Zamora, Spain Hospital Lozano Blesa Zaragoza, Spain Less << |
| NCT02028650 | - | Completed | - | China, Beijing ... More >> Affiliated Hospital of Academy of Military Medical Sciences Beijing, Beijing, China, 100071 Less << | |
| NCT00696735 | Follicular Lymphoma | Phase 3 | Completed | - | France ... More >> Emmanuel GYAN Tours, France, 37000 Philippe COLOMBAT Tours, France, 37000 Less << |
| NCT00184041 | Acute Lymphoblastic Leukemia | Phase 2 | Completed | - | United States, California ... More >> USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States, 90032 Less << |
| NCT01700946 | Recurrent B-Cell Childhood Acu... More >>te Lymphoblastic Leukemia Recurrent Childhood B-Lymphoblastic Lymphoma Less << | Phase 2 | Recruiting | October 2021 | United States, California ... More >> Rady Children's Hospital and Health Center Completed San Diego, California, United States, 92123 United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Sima Jeha, MD 866-278-5833 referralinfo@stjude.org Principal Investigator: Sima Jeha, MD United States, Texas Cook Children's Medical Center Recruiting Fort Worth, Texas, United States, 76104 Contact: Kenneth M. Heym, MD 682-885-4007 Principal Investigator: Kenneth M. Heym, MD Less << |
| NCT00186875 | Acute Lymphoblastic Leukemia ... More >> Lymphoma, Lymphoblastic Less << | Phase 2 | Completed | - | United States, California ... More >> Rady Children's Hospital and Health Center San Diego, California, United States, 92123 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 Less << |
| NCT00186875 | - | Completed | - | - | |
| NCT01960192 | Primary CNS Lymphoma (PCNSL) | Phase 4 | Recruiting | June 2020 | China, Henan ... More >> Oncology Department of The First Affiliated Hospital of Zhengzhou University Recruiting Zhengzhou, Henan, China, 450052 Contact: Mingzhi Zhang, Pro,Dr 13838565629 mingzhi_zhang@126.com Less << |
| NCT00004916 | Lymphoma | Phase 1 Phase 2 | Completed | - | United States, Illinois ... More >> Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois, United States, 60611-3013 Less << |
| NCT06048107 | HLH | RECRUITING | 2025-09-30 | Zhao Wang, Beijing, 100050, Ch... More >>ina, China Less << |
Tags: Teniposide | VM26 | VM 26 | VM-26 | Topoisomerase | podophyllotoxin derivative | topoisomerase II inhibitor | 29767-20-2
Precautionary Statements-General | |
| Code | Phrase |
| P101 | If medical advice is needed,have product container or label at hand. |
| P102 | Keep out of reach of children. |
| P103 | Read label before use |
Prevention | |
| Code | Phrase |
| P201 | Obtain special instructions before use. |
| P202 | Do not handle until all safety precautions have been read and understood. |
| P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
| P211 | Do not spray on an open flame or other ignition source. |
| P220 | Keep/Store away from clothing/combustible materials. |
| P221 | Take any precaution to avoid mixing with combustibles |
| P222 | Do not allow contact with air. |
| P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
| P230 | Keep wetted |
| P231 | Handle under inert gas. |
| P232 | Protect from moisture. |
| P233 | Keep container tightly closed. |
| P234 | Keep only in original container. |
| P235 | Keep cool |
| P240 | Ground/bond container and receiving equipment. |
| P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
| P242 | Use only non-sparking tools. |
| P243 | Take precautionary measures against static discharge. |
| P244 | Keep reduction valves free from grease and oil. |
| P250 | Do not subject to grinding/shock/friction. |
| P251 | Pressurized container: Do not pierce or burn, even after use. |
| P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
| P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
| P262 | Do not get in eyes, on skin, or on clothing. |
| P263 | Avoid contact during pregnancy/while nursing. |
| P264 | Wash hands thoroughly after handling. |
| P265 | Wash skin thouroughly after handling. |
| P270 | Do not eat, drink or smoke when using this product. |
| P271 | Use only outdoors or in a well-ventilated area. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |
| P273 | Avoid release to the environment. |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
| P281 | Use personal protective equipment as required. |
| P282 | Wear cold insulating gloves/face shield/eye protection. |
| P283 | Wear fire/flame resistant/retardant clothing. |
| P284 | Wear respiratory protection. |
| P285 | In case of inadequate ventilation wear respiratory protection. |
| P231 + P232 | Handle under inert gas. Protect from moisture. |
| P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
| Code | Phrase |
| P301 | IF SWALLOWED: |
| P304 | IF INHALED: |
| P305 | IF IN EYES: |
| P306 | IF ON CLOTHING: |
| P307 | IF exposed: |
| P308 | IF exposed or concerned: |
| P309 | IF exposed or if you feel unwell: |
| P310 | Immediately call a POISON CENTER or doctor/physician. |
| P311 | Call a POISON CENTER or doctor/physician. |
| P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
| P313 | Get medical advice/attention. |
| P314 | Get medical advice/attention if you feel unwell. |
| P315 | Get immediate medical advice/attention. |
| P320 | |
| P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
| P321 | |
| P322 | |
| P330 | Rinse mouth. |
| P331 | Do NOT induce vomiting. |
| P332 | IF SKIN irritation occurs: |
| P333 | If skin irritation or rash occurs: |
| P334 | Immerse in cool water/wrap n wet bandages. |
| P335 | Brush off loose particles from skin. |
| P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
| P337 | If eye irritation persists: |
| P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
| P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P342 | If experiencing respiratory symptoms: |
| P350 | Gently wash with plenty of soap and water. |
| P351 | Rinse cautiously with water for several minutes. |
| P352 | Wash with plenty of soap and water. |
| P353 | Rinse skin with water/shower. |
| P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
| P361 | Remove/Take off immediately all contaminated clothing. |
| P362 | Take off contaminated clothing and wash before reuse. |
| P363 | Wash contaminated clothing before reuse. |
| P370 | In case of fire: |
| P371 | In case of major fire and large quantities: |
| P372 | Explosion risk in case of fire. |
| P373 | DO NOT fight fire when fire reaches explosives. |
| P374 | Fight fire with normal precautions from a reasonable distance. |
| P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
| P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
| P378 | |
| P380 | Evacuate area. |
| P381 | Eliminate all ignition sources if safe to do so. |
| P390 | Absorb spillage to prevent material damage. |
| P391 | Collect spillage. Hazardous to the aquatic environment |
| P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
| P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
| P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
| P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
| P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
| P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
| P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
| P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
| P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
| P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
| P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
| P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
| P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
| P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
| P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
| P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
| P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
| P370 + P376 | In case of fire: Stop leak if safe to Do so. |
| P370 + P378 | In case of fire: |
| P370 + P380 | In case of fire: Evacuate area. |
| P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
| P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
| Code | Phrase |
| P401 | |
| P402 | Store in a dry place. |
| P403 | Store in a well-ventilated place. |
| P404 | Store in a closed container. |
| P405 | Store locked up. |
| P406 | Store in corrosive resistant/ container with a resistant inner liner. |
| P407 | Maintain air gap between stacks/pallets. |
| P410 | Protect from sunlight. |
| P411 | |
| P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
| P413 | |
| P420 | Store away from other materials. |
| P422 | |
| P402 + P404 | Store in a dry place. Store in a closed container. |
| P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
| P403 + P235 | Store in a well-ventilated place. Keep cool. |
| P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
| P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
| P411 + P235 | Keep cool. |
Disposal | |
| Code | Phrase |
| P501 | Dispose of contents/container to ... |
| P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
| Code | Phrase |
| H200 | Unstable explosive |
| H201 | Explosive; mass explosion hazard |
| H202 | Explosive; severe projection hazard |
| H203 | Explosive; fire, blast or projection hazard |
| H204 | Fire or projection hazard |
| H205 | May mass explode in fire |
| H220 | Extremely flammable gas |
| H221 | Flammable gas |
| H222 | Extremely flammable aerosol |
| H223 | Flammable aerosol |
| H224 | Extremely flammable liquid and vapour |
| H225 | Highly flammable liquid and vapour |
| H226 | Flammable liquid and vapour |
| H227 | Combustible liquid |
| H228 | Flammable solid |
| H229 | Pressurized container: may burst if heated |
| H230 | May react explosively even in the absence of air |
| H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
| H240 | Heating may cause an explosion |
| H241 | Heating may cause a fire or explosion |
| H242 | Heating may cause a fire |
| H250 | Catches fire spontaneously if exposed to air |
| H251 | Self-heating; may catch fire |
| H252 | Self-heating in large quantities; may catch fire |
| H260 | In contact with water releases flammable gases which may ignite spontaneously |
| H261 | In contact with water releases flammable gas |
| H270 | May cause or intensify fire; oxidizer |
| H271 | May cause fire or explosion; strong oxidizer |
| H272 | May intensify fire; oxidizer |
| H280 | Contains gas under pressure; may explode if heated |
| H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
| H290 | May be corrosive to metals |
Health hazards | |
| Code | Phrase |
| H300 | Fatal if swallowed |
| H301 | Toxic if swallowed |
| H302 | Harmful if swallowed |
| H303 | May be harmful if swallowed |
| H304 | May be fatal if swallowed and enters airways |
| H305 | May be harmful if swallowed and enters airways |
| H310 | Fatal in contact with skin |
| H311 | Toxic in contact with skin |
| H312 | Harmful in contact with skin |
| H313 | May be harmful in contact with skin |
| H314 | Causes severe skin burns and eye damage |
| H315 | Causes skin irritation |
| H316 | Causes mild skin irritation |
| H317 | May cause an allergic skin reaction |
| H318 | Causes serious eye damage |
| H319 | Causes serious eye irritation |
| H320 | Causes eye irritation |
| H330 | Fatal if inhaled |
| H331 | Toxic if inhaled |
| H332 | Harmful if inhaled |
| H333 | May be harmful if inhaled |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| H335 | May cause respiratory irritation |
| H336 | May cause drowsiness or dizziness |
| H340 | May cause genetic defects |
| H341 | Suspected of causing genetic defects |
| H350 | May cause cancer |
| H351 | Suspected of causing cancer |
| H360 | May damage fertility or the unborn child |
| H361 | Suspected of damaging fertility or the unborn child |
| H361d | Suspected of damaging the unborn child |
| H362 | May cause harm to breast-fed children |
| H370 | Causes damage to organs |
| H371 | May cause damage to organs |
| H372 | Causes damage to organs through prolonged or repeated exposure |
| H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
| Code | Phrase |
| H400 | Very toxic to aquatic life |
| H401 | Toxic to aquatic life |
| H402 | Harmful to aquatic life |
| H410 | Very toxic to aquatic life with long-lasting effects |
| H411 | Toxic to aquatic life with long-lasting effects |
| H412 | Harmful to aquatic life with long-lasting effects |
| H413 | May cause long-lasting harmful effects to aquatic life |
| H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL


